AdvaMed, the MedTech Association, has issued a statement on the U.S. Department of Commerce's investigation into whether the U.S.’s current level of medtech imports has national security implications.
The investigation began on September 2 under section 232 of the Trade Expansion Act of 1962. The department invited interested parties to submit written comments, data, analyses, or other information related to the investigation.
AdvaMed President and CEO Scott Whitaker said the association looks forward to continuing its work with the Trump administration, including through the Commerce department’s investigation, "to strengthen our already-robust and uniquely American industry."
"We believe this process will reinforce the fact that U.S. medtech manufacturing is strong and lower tariffs will fuel more manufacturing and job growth in the U.S., which means greater access to lifesaving technologies and lower costs to American hospitals and patients," Whitaker said.
